Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oneness Biotech advanced its siRNA candidate SNS851 to the multiple-ascending dose part of a Phase 1 trial after completing SAD in healthy volunteers; MAD will enroll participants with fatty liver disease, with data expected in Q1 2027.Material DetailsContext by AI AnalystThis is an early-stage cli…
The Taiwan-based biotech said it completed the single-ascending dose portion of its phase 1 trial for SNS851 in healthy volunteers and is moving to multiple-ascending dose testing in participants with fatty liver disease. Data from the MAD portion are expected in Q1 2027.